Clinical trial
Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
NCT00484666 · Carilion Clinic, Other · Withdrawn
Key facts
| NCT number | NCT00484666 |
|---|---|
| Title | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
| Official title | A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
| Acronym | TopoTxt |
| Lead sponsor | Carilion Clinic, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Withdrawn |
| Study type | Observational |
| Conditions | Ovarian Cancer |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jun 11, 2007 |
| Last update posted | Sep 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: